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Abstract: Tuberculosis (TB) is an airborne communicable disease with high morbidity and mortality
rates, especially in developing countries. The causal agents of TB belong to the complex Mycobacterium
tuberculosis (MTBc), which is composed of different human and animal TB associated species. Some
animal associated species have zoonotic potential and add to the burden of TB management. The
BCG (“Bacillus Calmette-Guérin”) vaccine is widely used for the prevention against TB, but its use is
limited in immunocompromised patients and animals due to the adverse effects and disseminated
life-threatening complications. In this study, we aimed to carry out a comparative genome analysis
between the human adapted species including BCG vaccine strains to identify and pinpoint the
conserved genes related to the virulence across all the species, which could add a new value for
vaccine development. For this purpose, the sequences of 183 Mycobacterium tuberculosis (MTB) strains
were retrieved from the freely available WGS dataset at NCBI. The species included: 168 sensu stricto
MTB species with other human MTB complex associated strains: M. tuberculosis var. africanum (3),
M. tuberculosis var. bovis (2 draft genomes) and 10 BCG species, which enabled the analysis of core
genome which contains the conserved genes and some virulence factor determinants. Further, a
phylogenetic tree was constructed including the genomes of human (183); animals MTB adapted
strains (6) and the environmental Mycobacterium strain “M. canettii”. Our results showed that the core
genome consists of 1166 conserved genes among these species, which represents a small portion of the
pangenome (7036 genes). The remaining genes in the pangenome (5870) are accessory genes, adding a
high inter-species diversity. Further, the core genome includes several virulence-associated genes and
this could explain the rare infectiousness potential of some attenuated vaccine strains in some patients.
This study reveals that low number of conserved genes in human adapted MTBc species and high
inter-species diversity of the pan-genome could be considered for vaccine candidate development.
Keywords: tuberculosis; Mycobacterium tuberculosis; BCG vaccine; comparative genome analysis; core
genome; virulence; phylogeny
1. Introduction
Tuberculosis is an infectious airborne disease that (TB) evolved concomitantly with
human 70,000 years and has killed millions of people in this time [1,2]. Currently, a
quarter of the global population is infected with latent TB, and TB became the first leading
infectious disease killer in the world [3]. The etiological agents of TB belong to the complex
Mycobacterium tuberculosis (MTBc), which is composed of different human and animal TB
associated species. The human-associated MTB includes eight lineages: MTB sensu stricto
(L1–L4 and L7–L8) and M. africanum (L5 and L6) [4–6].
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The animal-associated MTBc includes M. bovis, M. microti, M. caprae, M. pinnipedii,
M. orygis, the dassie bacillus, M. mungi, M. suricattae, and the chimpanzee bacillus [5]. Some
of MTB human associated species are very restricted geographically to certain regions of the
world (L1, L5–L8), whereas others have a wider distribution and are considered as modern
MTB species (L2–L4). The latter species are more virulent, causing severe manifestations
and have many strains associated with anti-tuberculosis drug resistance [4].
According to the latest reports from the World Health Organization (WHO) in 2019,
there were an estimated 10.0 million new TB cases and 1.2 million deaths worldwide [3].
Further, a zoonotic form of tuberculosis, caused by M. bovis (a member of MTB complex)
added to the burden (an estimated 143,000 new cases with a range of 71,000–240,000 in
2018) and caused enormous economic losses [7]. M. bovis has a wide range spectrum
of hosts, including domesticated animals like cattle, goats, pigs, cats, dogs, horses, and
sheep [8], and also wild animals including brush tail possum, badger, buffalo, wood bison,
wild boar, and white-tailed deer [9,10].
The MTB bacillus is highly infectious, contagious and has a long infectiousness period;
a person with an active TB infection can infect 5 to 15 people via close or direct contact.
Despite the international efforts to fight against TB, the problems of epidemic expansion
and continuity of infection are still persistent. The reduced efficacy of the BCG vaccine and
its limited use in animals and serious complications in immunocompromised patients [11];
altogether with the emergence of different forms of drug resistance lead to a massive
number of deaths that exceeds that of HIV and malaria combined in the last 3 three years.
The uniqueness of the MTB bacilli is attributed to different phenotypic, immunologic,
and genomic characteristics. Phenotypically, the MTBc species have acid fastness ability
due to high lipid and mycolic acid content in the cell wall; they grow slowly on ordinary
media cultures and have an obligate intracellular life style. Immunologically, the latency of
the tubercle bacilli within the host is a remarkable feature due to their ability to evolve, con-
struct new environmental niches and reshape the host cell signals to enhance stochastically
their fitness and ability to reactivation and transmission [12].
Genomically, the MTBc members share high similarity at nucleotide level and 16Sr-
RNA phylogeny analysis [8]. The MTB species are among the high GC content bacteria,
which have different genes associated with the metabolism of lipids and cell wall, provid-
ing them the ability to escape macrophages. The members of the complex MTB, like other
pathogenic mycobacteria, have been undergoing genome downsizing, losing many genes
associated with free living style and keeping genes essential for pathogenicity, virulence
and survival in the host cell [13,14]. Likewise, the MTBc members acquired new genes,
adapting them to new host niche and overcoming its immune system barriers [13].
Several studies showed that MTB strains evolved from an ancestral-environmental
mycobacterium, named M. canettii (smooth TB) through horizontal gene transfer, which is
uncommon within MTBc species [4,13]. The regions of difference (RD) or large sequence
polymorphisms (LSPs) have been considered as gold standards for the differentiation
between the members of the MTBc and phylogenetic analysis [15]. Most of human adapted
species have (RD1–RD10) regions, except M. africanum strains L6 sharing a common
progenitor with animal-adapted species and lost the RD9 region. M. africanum (MAF) is
restricted to the region of Western Africa; it was also isolated in African immigrants in
industrialized countries. MAF has a closer relatedness to MTB sensu stricto strains in the
pattern of RD than M. bovis [16]. Further, Ngabonziza et al. have recently found a sister
clade (L8) of MTBc members, which is characterized by the lack of RD3, RD5, and RD14 [6].
L8 is restricted to the African Great lakes regions in Rwanda and Uganda and showed
to be diverged prior to the loss of cobF gene, associated with vitamin B12 synthesis. The
cobF gene is still available in M. canettii and some free living mycobacteria [6]. The animal
adapted species also lack RD7, RD8, RD10 [4,17].
The human adapted modern MTB species (L2–L4) lost a specific region TbD1 including
two genes MmpS6 and MmpL6, which lead to virulence enhancement and global epidemic
transmission through the resistance against oxidative stress and hypoxia [18].
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In addition, all attenuated BCG vaccine strains lack the RD1(Rv3868 to Rv3875 and
Rv3877), which encodes an ESX-1 secretion system [19]. This contains different genes
related to virulence, mainly two important genes esxA and esxB encoding ESAT-6 and
CFP-10 antigens, respectively [4,19]. By manipulating the parental BCG strains, new
BCG vaccine strains were developed with different virulence levels and immunological
efficacy [20].
Deepening in the genomics of human associated TB species and available vaccine
strains could reveal new insights about the improvement of BCG efficacy and its use in
human or animals. With the availability of ongoing whole genome sequencing datasets,
comparative genomics tools could provide an insightful vision about the evolutionary
events within an infectious agent and help to identify genes conserved across all the species
and decipher the unique genes that give differential and special characteristics related to
virulence and pathogenicity and consequently facilitate identifying new target genes for
vaccine development [4,17].
In this study, we carried out a comparative genome analysis of 168 sensu stricto MTB
species with other human MTBc: M. tuberculosis var. africanum (3), M. tuberculosis var. bovis
(2), 10 BCG species through the freely available WGS dataset at NCBI, which enabled the
analysis of core genome and virulence factors determinants across all the species. Then,
a phylogenetic tree was constructed based on core genome including the genomes of
human (183); some animals adapted MTB strains (6) and the environmental Mycobacterium
“M. canettii”.
2. Materials and Methods
2.1. Genome Sequencing and Annotation
All the complete genomes of MTBc (181) and two draft genomes isolates (total of
183 genomes) were obtained from NCBI: http://www.ncbi.nlm.nih.gov/ (accessed on
2 February 2020) GenBank, available sequences on 2 February 2020 were retrieved and
analyzed for the purpose of comparative genome analysis. The species includes 168 sensu
stricto MTB species with other human associated TB strains: M. tuberculosis var. africanum
GM041182, M. tuberculosis var. africanum UT307, M. tuberculosis var. africanum strain 25, M.
tuberculosis var. bovis MBE9, and M. tuberculosis var. bovis strain MAL010093 (draft genome
were included) M. tuberculosis var. bovis BCG strains (10). For the phylogeny analysis, the
genomes of some animal adapted-MTB strains (M. tuberculosis var. bovis strain AF2122/97,
M. mungi, M. orygis, M. tuberculosis var. microti, M. tuberculosis var. caprae and M. tuberculosis
var. pinnipedii) and the environmental Mycobacterium strain “M. canettii” were included. M.
tuberculosis var. bovis strain AF2122/97 and “M. canettii” have complete genomes and the
remaining animal strains have draft genomes.
2.2. Orthologous Gene Prediction and Genome Sequence Comparison
Orthologous proteins for 184 Mycobacterium tuberculosis genomes were identified
by the comparison of all the species against each other by the use of blastp and the
application of the default scoring matrix BLOSUM62 and an initial-value cut-off of 1 × 10−5.
Normalizing of the raw BLAST hit scores against the maximum possible score (defined
here as the self-hit score for each gene) was performed. This resulted in a score ratio value
(SRV) between 0 and 100 that showed the quality of the hit much better than the raw blast
bit score.
Two proteins were considered orthologous if a reciprocal best blast hit existed between
them, and both hits had an SRV > 32. The SRV threshold is computed from distribution
of blast hits between analyzed sequences as described in the supplement of Blom et al.
(2009) [21]. Based on this orthology principle, the core genome was calculated as the set of
genes that had orthologous proteins in all other analyzed strains.
The pan-genome was estimated as the set of all unique proteins of a set of genomes.
All proteins of one reference genome were considered the basic set for the calculation.
Afterwards, the proteins of a second genome were matched with this set, and all proteins
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in the second genome that had no orthologous proteins in the starting proteins set were
added to this set. This process was iteratively repeated for all genomes of the compared
set, leading to the pan-genome.
2.3. Phylogenetic Tree Construction
A phylogenetic tree was constructed with a modified version of the pipeline designed
by Zbodnov and Bork as described by blom et al. (2009) [21]. Alignments of the core
gene sets were compiled using MUSCLE [22], the numerous resulting multiple alignments
were concatenated, and poorly aligned positions were removed using GBLOCKS [23].
A trimmed multiple alignment system was used to create a phylogenetic tree using the
neighbor-joining operation of PHYLIP [24].
3. Results
3.1. General Features
In this study, we present a comparative genome analysis of 183 MTB strains obtained
from complete genome (181) and draft genome sequences (2) of human MTB adapted
strains. Additional sex genomes of different animal MTB-adapted strains and M. canettii
were also considered for the phylogeny analysis.
The length of the complete genomes ranged between 4.3 to 4.4 MB, with a number
of genes between 3670 to 4826 with a high GC content (65.01–65.07%). The numbers of
predicted protein-encoding open reading-frames proteins ranged between 3622 to 4778
(Supplementary Table S1 summarizes a number of characteristics for each genome).
3.2. Core and Pan Genome
The pan genome compares the genomes of different strains from the MTB complex as
the mean for determining the overall genetic content of a given species. Several genetic
loci from the pan genome needed for the bacterial survival forms the core genome of a
particular species. Most of these genes are essential for basic housekeeping functions. The
dispensable genome of a species consists of the genetic content of a species, which is present
only in a subset of strains and is believed to play important roles in phenotypic variation
and genome evolution. The pan genome of 183 complete and draft genomes of MTB strains
consists of 7036 genes (Table S2) of which 1166 (16.6%) formed the core genome (Table S3).
Out of the 1166 core genes 347 were either hypothetical proteins or proteins with unknown
function. The remaining genes are essential genes associated with replication, DNA repair,
protein translation and regulation, synthesis of mycolic and fatty acids, transcriptional
regulation, energy metabolism, catabolism, virulence, and other functions.
The dispensable genome of entire MTB strains consists of 5870 genes revealing high
inter-species diversity (Figure 1). Furthermore, a careful study of the pangenome develop-
ment data revealed an α-value of 0.872, which is rather high, indicating that the pangenome
curve starts to flatten at approximately 120 genomes. Genomes added after that contribute
only few genes to the pangenome implying the pangenome of 183 MTB strains is eventually
proceeding to a closed status representing the entire genetic repertoire of MTB species. A
similar pattern was observed with the core genome development plot.
3.3. Phylogenetic Analysis
A phylogenetic tree was constructed based on the extracted multiple alignment of the
1059 core proteins from all 190 genomes. The results of phylogenetic analyses are shown
in Figure 2; remarkably, based on the core genome phylogenetic tree, the 190 (human and
animal MTB adapted strain) MTBc strains were grouped into four clades (Figure 2). The
first, third and fourth clades were composed of sensu stricto MTB species. However, M.
tuberculosis var. africanum, M. tuberculosis var. bovis human adapted strains were clustering
with animal adapted strains and M. canettii”, showing a shared common ancestor.
Antibiotics 2021, 10, 500 5 of 11Antibiotics 2021, 10, x FOR PEER REVIEW 5 of 11  
 
Figure 1. MTB pan/core genome. The core genome is listed with orange background and the all 
the remaining genes (dispensable) part of the pan genome are listed with the green background. 
3.3. Phylogenetic Analysis 
A phylogenetic tree was constructed based on the extracted multiple alignment of 
the 1059 core proteins from all 190 genomes. The results of phylogenetic analyses are 
shown in Figure 2; remarkably, based on the core genome phylogenetic tree, the 190 (hu-
man and animal MTB adapted strain) MTBc strains were grouped into four clades (Figure 
2). The first, third and fourth clades were composed of sensu stricto MTB species. How-
ever, M. tuberculosis var. africanum, M. tuberculosis var. bovis human adapted strains were 
clustering with animal adapted strains and M. canettii”, showing a shared common ances-
tor. 
The vertical line at the beginning of Figure 2 (in this case, 0.01) is used to provide a 
rough measure of genetic distance. Furthermore, the pattern of clustering confirms a high 
similarity between the MTBc members and is in accordance with other previous studies. 
No clear clustering emerged from the geographical location or niche of these strains. 
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The vertical line at the beginning of Figure 2 (in this case, 0.01) is used to provide a
rough measure of genetic distance. Furthermore, the pattern of clustering confirms a high
similarity between he MTBc m mbers and is in accordance with other previ us studies.
No clear clustering emerged from t geographical location or niche of these strains.
3.4. Clade Specific Analysis Based on Phylogenetic Tree
Four clades derived from the phylogenetic tree and represented in different colors
in Figure 2. These clades were inspected for clade specific genes to investigate if there is
something specific in these clades that lead to four different clusters in the phylogenetic
tree. For each clade we looked for genes present in all the genomes of a particular clade but
absent in all other MTB strains. Apart from a few hypothetical proteins, the clade specific
analysis did not produce any significant set of genes specific to each clade. The analysis of
each clade species shows very high similarity among MTB strai s. Further, we checked
14 Regions of RD and also TbD1, which are all absent in the core genome.
However, some of the remaining genes are related to pathogenicity and virulence and
Table 1 showed all the virulence related genes in this collection.
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Table 1. Virulence conserved genes in the core genome, according to Forrellad et al. [25].
RV Number or Gene in the Core Genome Role of Virulence Factor
Rv3615c (espC), Rv3867 (espH), Rv1539 (lspA), Rv1791 Secretion system
Rv2936 (DrrA), Rv2937 (DrrB), Rv2938 (drrC): daunorubicin ABC transporter Synthesis of Phthioceroldimycocerosates (PDIM)
Rv0642c (mmaA4) Mycolic acid synthesis(hydroxymycolate synthase)
Rv3568c (hsaC), Rv3541c Catabolism of cholesterol
Rv0167, Rv0170, Rv0173 (mce operon 1), Rv0589 (part of operon Mce2A), Rv0199 Cell wall and conserved membrane proteins
Rv1410c, Rv1235 (lpqY) Lipoproteins
Rv2031c, acr1 alpha-crystallin (hspX) Inhibition of macrophage effectors
Rv1941, Rv1932 (tpX), Rv2234 (ptpA) Oxidative/nitrosative stresses
Rv3133c (devR), Rv3132c (dosR), Rv2745c (clgR), Rv0353 (hspR), Rv3416 (whiB3),
Rv0348 (mosR), Rv3082c (virS), Rv0821c PhoY2, Rv0990c, Rv0491 (regX3) transcriptional regulators
Rv2115c (mpa) Mycobacterial proteasome ATPase
Rv0758 (phoR), sensor kinase of phosphate regulon Gene Expression Regulator
Rv2069 (sigC), Rv3414c (sigD), Rv1221 (sigE), Rv3223c (sigH), Rv0735 (sigL) Sigma factors: RNA polymerasesigma factors
Rv2711 (ideR) iron-dependent repressor and activator
Rv1811 (mgtC) Mg2+ transport P-type ATPase Metal importers
Rv0990c conserved heat shock protein (hsp22.5) Other mycobacterial virulence factors
4. Discussion
Tuberculosis is the leading cause of death as an infectious agent and M. tuberculosis, the
etiological agent succeeded to co-evolve, adapt, and interact reciprocally with the human
beings through the years. The human adapted MTBc strains share a high relatedness
at genomic level and differ in geographic distribution, virulence, transmissibility, and
drug resistance pattern. Currently, the MTBc species: M. tuberculosis var. africanum, M.
tuberculosis var. bovis, M. tuberculosis var. caprae, M. tuberculosis var. microti, and M.
tuberculosis var. pinnipedii are considered as heterotypic variants of M. tuberculosis [26]. In
addition, M. canettii M. orygis and M. mungi are strains of the species M. tuberculosis [26].
There have been several pan/core genomic studies on MTBs but most have been based on
fewer numbers of genomes [27,28]. Other large-scale studies on core/pan-genome analysis
showed the utility of this tool to study the genetic difference within species and to identify
the known and novel genetic signature of genes conferring resistance [29,30].
Thus, we decided to take all the complete genomes of MTBs available and report
the complete genetic repertoire of the species. In the present study, we carried out a com-
parative genome analysis of 183 MTBc human associated species including 168 sensu
stricto MTB species, M. tuberculosis var. africanum (3), M. tuberculosis var. bovis (2),
10 M. tuberculosis var. bovis BCG vaccine species through the freely available WGS dataset at
NCBI, which enabled the calculation of the core-genome across all the species and to reveal
the main virulence conserved genes. Then, based on the core genome, we constructed a
phylogenetic tree by the use of human (183), animals MTB adapted strains (6), and the
environmental Mycobacterium pathogen “M. canettii”.
Genome size, number of genes, and number of proteins varied according to the species,
and thus considerably correlated with size of pan genome consisting of 7036 genes, which
comprised all the genes encoding proteins in all the species including the accessory genes
and core genome. In contrast, the core genome of 1166 genes was represented by the
minimal set of indispensable conserved genes across all the species [14]. Even though, the
number of core genes are only about 17% of the overall pan genome this is still quite large
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and in line with previous studies. These core genome genes provide the identity of MTBc
human associated species and exist in each strain included in this study. As expected,
all the 14 Regions of RD and TbD1 that have been used for the discrimination between
the MTBc lineages are absent in the core genome, which includes only conserved genes
across all the species. Most of the conserved genes are associated with DNA replication,
repair, translation, transcription regulation, synthesis of fatty acids and mycolic acid, and
metabolism and catabolism of macromolecules. In a previous study, Yang et al. studies
49 MTB, M. bovis and BCG vaccine species and identified 3679 conserved genes and only
1122 accessory genes, which contradict our study and reveal the importance of including
more strains for having a clear vision about the evolution of MTBc strains. Some of the
genes in the core-genome were among the optimal required genes for the in vitro and
in vivo growth stated by Zhang et al., 2012 and Sassetti et al., 2003 [31,32]. However, all
those genes were available in the pan-genome. Both studies were based on the analysis of
the virulent reference strain M. tuberculosis H37 Rv.
The core genome results of human adapted MTBc strains showed that BCG vaccine
strains still share several genes associated to virulence and persistence of pathogen within
the host.
For instance, despite the absence of RD1 genes encoding the Esx1 of the secretion
system in the core genome, the espC gene is still conserved in all the MTBc species included
in this study. The espC has a high similarity in sequence, size and an equivalent immun-
odominancy to CFP-10 and ESAT-6, which are able to engender cellular immunity [33].
The Phthiocerol dimycocerosates (PDIM) is another putative virulence factor in the MTBc
complex members and other slow growing mycobacteria and plays an essential role in
the phagosomal rupture induced by the tubercle bacilli [4]. The conserved drrABC operon
(daunorubicin ABC transporter) and especially the drrC, which is involved in the transport
of PDIM indicates a certain level of virulence among the species. Significantly, mutant MTB
strains harboring inactivated drrB and drrC were not able to secrete PDIM [34].
The PhoR or the two-component system response sensor kinase is also among the
conserved virulence genes found in the core genome. In addition to its role as a transcrip-
tional regulator, this gene showed a key evolutionary role in MTBc host speciation after a
functional divergence followed by positive selection from the common ancestor and transi-
tion from free living to a host specific intracellular parasitic life style [35]. Interestingly, the
DU2-III BCG vaccine strains like Glaxo and Danish (not included in this study) showed
a deletion of 10 nucleotides in codon 91 of PhoR, which could be associated with more
attenuation in these strains [36].
BCG vaccine has been used for several years for the prevention of different mycobac-
terial diseases like TB, Bruli ulcer, and leprosy. It is also useful for the treatment of some
non-communicable diseases, mainly an adjunctive biotherapy bladder cancer. Most re-
cently, it showed to have some efficacy against COVID 19 [37]. Despite the deletion of
the RD1 region that lead to the attenuation of its infectivity, the BCG vaccine could be
disseminated in some cases and provoke life-threatening infections in immunocompro-
mised patients including HIV-infected and severe combined immunodeficiency (SCID)
patients. In 2007, the WHO stopped recommending the use of BCG vaccination for HIV
infected children due to the deleterious risk of BCG disseminated infection or BCGosis,
which could be engendered by its use [11]. Recently, it showed also the same effect on
cancerous patients treated with or without intravesical instillation, causing pulmonary
TB, which is sometimes associated with extrapulmonary manifestations and very serious
complications [38,39].
The development of new vaccines is challenging in the field of mycobacteriology and
ensuring the safety and efficacy and lowering the adverse effects of a vaccine are major
health priorities with the emergence of multi drug resistant strains and incurable forms of
TB. Recent comparative genome analysis of BCG vaccine strains showed that engineering
the BCG strains through the years lead to the loss of important component including
T-cell epitopes and restoring and manipulating some epitopes could offer new solutions for
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vaccine development [20]. Reintroducing some deleted RD regions or some of their proteins
in new BCG vaccine candidate could stimulate and increase the protective immunity [40].
For instance, a recent study showed that the integration of the RD4 (Rv1506c-Rv1516c) in
BCG vaccine strain increased the protection against M. marinum in zebrafish model [41].
Our phylogenetic analysis is in accordance with other several studies; showing a high
similarity and clustering pattern between the MTBc members and confirming that the
MTBC members are sharing the same ancestor in their evolutionary events and a high
relatedness [13]. The MTBc strains were grouped into four clades. The first, third and fourth
clades included MTB sensu stricto and the second clade is represented by M. tuberculosis var.
africanum (L5 and L6), M. tuberculosis var. bovis, all the animal adapted MTBc strains and
all the BCG vaccine strains. BCG vaccine strains are attenuated derivatives M. tuberculosis
var. bovis and share very high similarity with each other despite their immunogenicity and
virulence level.
Most modern MTBc species from lineages L2, L3, and L4 are world-widely distributed,
more virulent and many of them associated with drug resistance, especially Beijing strain
(L2). The results of the clade specific analysis based on phylogenetic tree are also with
concordance with the phylogeny results and confirm that all the species have a distinct
and common pathway of the evolutionary bottleneck and a clonal expansion toward more
speciation to the intracellular niche of human macrophages [42].
The core genome represents only 16.6% of the pan genome, which indicates that most
acquired genes are conferring more functionality, complexity, and diversity. However, our
results showed that the pan genome was flattened after 120 genomes and proceeded to a
closed pan genome status, confirming an allopatric and sympatric geographic speciation
of MTBc complex members, which correlates with pathogen–host interactions and this
explains the different severity and persistence patterns of MTB species within the host [43].
5. Conclusions
To conclude, our results showed that despite the high phylogenetic relatedness be-
tween the MTBc species, the core genome represents only a small portion of the pan-genome
and still contains several virulence factors, which can be exploited for further diagnostic
and vaccine development.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/antibiotics10050500/s1, Table S1. A general overview of 190 MTB genomes. Table S2. The pan
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